Alpha Tau Medical (DRTS)
(Delayed Data from NSDQ)
$2.29 USD
+0.01 (0.44%)
Updated Nov 6, 2024 02:38 PM ET
After-Market: $2.28 -0.01 (-0.44%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.29 USD
+0.01 (0.44%)
Updated Nov 6, 2024 02:38 PM ET
After-Market: $2.28 -0.01 (-0.44%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Alpha Tau Medical (DRTS) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alpha Tau Medical Ltd. (DRTS) and Regeneron (REGN) have performed compared to their sector so far this year.
Best Momentum Stocks to Buy for January 8th
by Zacks Equity Research
AKYA, DRTS and TRUP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 8, 2024.
New Strong Buy Stocks for January 8th
by Zacks Equity Research
TIMB, AKYA, DRTS, TRUP and QSG have been added to the Zacks Rank #1 (Strong Buy) List on January 8, 2024.
Down -20.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Alpha Tau Medical Ltd. (DRTS)
by Zacks Equity Research
Alpha Tau Medical Ltd. (DRTS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect an improvement at the Animal Health segment.
Is a Beat Likely for Cooper Companies (COO) in Q2 Earnings?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter results are likely to reflect segmental strength.
Should You Buy Alpha Tau Medical (DRTS) Ahead of Earnings?
by Zacks Equity Research
Alpha Tau Medical (DRTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.